The clinical trials listed below are for informational purposes only and are not endorsed by the AST/Power2Save. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.
Clinical Trials for Kidney Recipients
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as Adjunctive Treatment For Refractory Antibody-Mediated Rejection (ARMOR) in Adult Renal Transplant Recipients
Sponsor: CSL Behring
Organ Type: Kidney
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: Thursday, January 15, 2026
A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants
Sponsor: Medeor Therapeutics, Inc.
Organ Type: Kidney
Ages Accepted: Age ≥18 and ≤70 years
Genders Accepted: Both male and female
Expected Study Completion Date: January, 2022
A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
Sponsor: Novartis
Organ Type: Kidney
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: April 15, 2026
Clinical Trials for Other Organ Types
Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Sponsor: Atara Biotherapeutics
Organ Type: All organs
Ages Accepted: All ages
Genders Accepted: Both male and female
Expected Study Completion Date: Monday, November 30, 2020
Other Requirements
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant (RR) to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Sponsor: Takeda Pharmaceutical Company Limited
Organ Type: Hematopoietic Stem Cell Transplant, All organs
Ages Accepted: ≥12 years of age
Genders Accepted: Both male and female
Expected Study Completion Date: Tuesday, September 29, 2020
Other Requirements
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Sponsor: Takeda Pharmaceutical Company Limited
Organ Type: Hematopoietic Stem Cell Transplant
Ages Accepted: ≥16 years of age
Genders Accepted: Both male and female
Expected Study Completion Date: Tuesday, August 13, 2021
Other Requirements
A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additional Follow-up (CONTRAIL I)
Sponsor: Novartis
Organ Type: Liver
Ages Accepted: 18 years to 70 years
Genders Accepted: Both male and female
Expected Study Completion Date: September 23, 2022
